JPMorgan Downgrades GlaxoSmithKline (GSK) to Underweight
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Price: $49.52 -0.96%
Rating Summary:
6 Buy, 16 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 16 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
JPMorgan downgraded GlaxoSmithKline (NYSE: GSK) from Neutral to Underweight, saying 2013 earnings are at risk. The firm cut 2013 EPS by 12% and FY14-FY16 by 6-9%.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $46.07 yesterday.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $46.07 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Diana Shipping withdraws bid to acquire Genco Shipping
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
Create E-mail Alert Related Categories
DowngradesRelated Entities
JPMorgan, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
